The combination of ivosidenib plus azacitidine significantly prolonged OS with a median of 24.0 months compared with 7.9 months with placebo plus azacitidine.
Researchers sought to determine whether guadecitabine would have an overall survival benefit for patients with relapsed/refractory acute myeloid leukemia.
Researchers sought to determine whether zanubrutinib would improve survival in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
Researchers sought to determine whether lisocabtagene maraleucel would improve outcomes compared with standard of care in second-line therapy in patients with LBCL.
A bendamustine-based regimen performed similarly to high-dose melphalan in conditioning prior to autologous stem cell transplantation for multiple myeloma.